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Managed care organizations (MCOs) use many pharmacy benefit management tools and techniques to help guide appropriate medication usage. Popular methods are formularies, prescription drug caps, patient copayments, maximums, mandatory use of generics, drug-utilization review, and therapeutic interchange. The challenge faced by many MCOs is to deal with rising drug costs while not denying or limiting access to those drugs that improve therapeutic outcomes and health-related quality of life (HRQoL). The challenge is likely to become more difficult; prescription drug expenditures in the United States are projected to increase 11.0% in 2001 and 10.7% in 2002. 2 One pharmacy benefit management technique being used with increasing frequency is prior, or special, authorization (PA); a recent survey revealed that in 1996 43%, in 1997 54%, and in 1998 61% of employers reported using PA programs. 3 PA is an administrative tool that requires the prescriber to get pre-approval for prescribing a drug in order to qualify for reimbursement. 4 The broad purpose of PA is to change prescribing behavior. 5 The goal of the PA process is to encourage appropriate use of medications, both to reduce the incidence of preventable drug-related morbidity and to contain costs. The philosophy behind this mechanism, which intuitively seems to help promote the delivery of quality health care, is to target new, costly, or potentially toxic medications, and to encourage use of less-expensive, safer alternatives. Some view this technique as simply a means to contain costs rather than a qualityimprovement or risk-management tool.
Not all agree with the use of PA to direct prescribing. Understandably, the pharmaceutical industry views PA programs as a barrier to market access. Similarly, patients often feel that PA programs impede their access to drugs that they perceive as necessary. Many physicians are exasperated by the time dedicated to PA paperwork. Some physicians in New Brunswick, Canada, reported filling out up to 10 PA forms a day; in September 2000, physicians in the province refused to fill out any PA forms because of the time burden. 6, 7 Some physicians feel that PA programs actually prevent their patients from getting the medications they need in a timely manner. A survey in Ontario, Canada, revealed that only 34% (17 of 50) of the physicians who responded felt that a limited-use (PA) listing for medications helped them to more Sixty-six percent (29 of 44) said that in the past they have chosen not to prescribe a product primarily because of its limited-use status, even though the physician felt the patient might benefit from the drug. 8 Community pharmacists also complain about the administrative burden of PA programs; a recent study showed that, on average, a supermarket chain pharmacy spent 2.15 minutes and an independent pharmacy spent 2.97 minutes just on rejection resolution for each prescription that required PA. 9 Last year, the North Carolina Board of Pharmacy passed special regulations to help reduce community pharmacists' burdens of dealing with third-party payor administrative policies such as PA. 10 Perhaps the greatest controversy over the use of PA is the unintended effect of other prescribing restrictions such as restrictive formularies and benefit caps. One of the first studies to document unintended effects was a 1985 study of a closed formulary for drugs used in treating peptic ulcer disease for the West Virginia Medicaid program. After a formulary policy change, outpatient drug expenditures were reduced by 78.9%, but monthly physician payments increased 3.1% and monthly inpatient hospital costs increased 23.6%.
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A 1991 study found that drug use decreased but nursing home admissions increased after a three-prescription limit per patient per month was implemented in the New Hampshire Medicaid program. 12 A controversial 1996 study by Horn and colleagues further added to the literature on the unintended effects of prescribing restrictions by concluding that health maintenance organizations (HMOs) with more-restrictive drug formularies had higher overall utilization and costs of health care resources. 13 There has been considerable debate over the methodology of the Horn study in particular and over prescribing restrictions in general, including several editorials in this journal. 14 Since PA programs are common in the managed care pharmacy environment, and because of the questions about these programs stimulated by previous studies, we considered it urgent to examine the effectiveness of PA programs. The objective of this article is to review the peer-reviewed literature on PA programs and to assess their effects on economic, clinical, and humanistic outcomes of health care.
¨¨Methods

Data Sources
A computer-aided search of the medical and pharmacy literature in English was conducted in spring 2001, using Medline, International Pharmaceutical Abstracts (IPA), Health Star, and Ecolit. Keywords such as prior authorization, prescribing restrictions, prior approval, special authorization, cost containment, exception drug status, and restrictive formularies were used in the search. Other studies on PA were found in managed care textbooks, references, and reading materials previously collected by the lead author. We attempted to contact authors of published studies on PA and researchers on PA in search of studies that were not identified by our computer-aided search. We reviewed abstracts from recent educational conferences and annual meetings of the Academy of Managed Care Pharmacy (AMCP) and annual meetings of the Canadian Association of Population Therapeutics (CAPT), but a study had to be published in complete form in order to be included in our final analysis.
Study Selection
In order for a study to be included in our analysis, it had to (1) appear in the peer-reviewed literature, and (2) investigate the effects of a PA program on specified drugs. We excluded papers that studied the effectiveness of formulary systems, of which prior authorization may be a component, as it would be impossible to distinguish the effect of the PA program from the effect of the formulary itself.
¨¨Data Extraction
From each study evaluated, we extracted data related to the study design and the effect of the PA programs on health-related outcomes. In the critique of each study, each author of this article independently used a standardized data collection form based on the ECHO (economic, clinical, and humanistic outcomes) model proposed by Kozma, Reeder, and Schulz as our framework for evaluation. 15 More specifically, for all studies we critically evaluated the methodology, study sample, outcomes measures, drugs studied, and economic (both drug costs and other health expenditures), clinical (both drug-related and non-drug-related), and humanistic outcomes (satisfaction and HRQoL).
¨¨Results
Six studies met our criteria for review. 5, [16] [17] [18] [19] [20] The study design, study sample, outcomes measures, and drugs in the PA programs are contained in Table 1 , page 299.
Because no study had a randomized, controlled experimental design, all studies had significant threats to validity. The study by Smalley and colleagues had the most rigorous experimental design. 17 Four of the six studies had no control group.
5,
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One study did not use a baseline measurement period before the PA program was set up, and only one study had a follow-up period of more than one year to measure the long-term effects of the PA program. 18, 17 Four of the six studies used a state Medicaid program for the study sample. 5, [16] [17] [18] The other studies used an urban teaching hospital and secondary data from a national survey. 19, 20 None of the studies was multi-center. The intended unit of analysis was often hard to determine; indeed, three of the studies did not specify the exact number of patients considered. 5, 18, 19 Outcome measures also varied considerably. One study measured simply the cost and utilization of the PA drugs. 18 Only one study included clinical outcome measures. 19 Four of the studies looked at a single drug class (nonsteroidal anti-inflam-
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Prior Authorization Programs: A Critical Review of the Literature Prior Authorization Programs: A Critical Review of the Literature matory drugs [NSAIDs] in two, intravenous antibiotics in one, topical tretinoin in one), while the two others evaluated several drug classes. Table 2 , page 300, contains the economic, clinical, and humanistic outcomes that were measured in these studies. We distinguished between drug and non-drug outcomes in both the economic and clinical outcome categories and between patient satisfaction and HRQoL humanistic outcomes.
All six studies documented drug cost savings from the PA programs. We had initially hoped to conduct a meta-analysis to better summarize the amount of drug cost savings from PA programs, but inconsistencies in the descriptions of the study samples and outcomes made it impossible to calculate an effect size. It is interesting, though, that the two studies that focused on a PA program for NSAIDs found similar drug cost savings (approximately 54% in Kotzan et al. and 53% in Smalley et al.). 16, 17 Some studies failed to distinguish between cost savings resulting from lower overall drug product cost (switch to generic or less expensive drug) or from lower drug utilization.
Of the three studies that measured the effect of the PA program on non-drug costs, none found a significant increase in costs elsewhere in the health care system. 16, 17, 19 Five of the six studies calculated the administrative costs of operating the PA program, although they did not provide thorough descriptions of how these costs were measured, what they included, and costs to stakeholders outside of the direct organization of interest (e.g., community pharmacists, physicians, etc.). 5, [17] [18] [19] One study concluded that the administrative costs of the PA program outweighed the reduction in drug costs for a majority of age groups considered. 20 Only the study by White and colleagues measured how the PA program affected clinical outcomes. 19 None of the studies measured how PA programs affected satisfaction (patient, pharmacist, physician, nurse, or other) or HRQoL, two primary humanistic outcomes.¨D iscussion Our critical analysis of the literature indicates that although PA programs are common, their outcomes have not been adequately evaluated. PA is not alone, however; evaluation of administrative policies and programs in health care and in pharmacy benefit management today is rarely adequate. 12, 21 Still, the scarcity of quality evaluations of the outcomes of PA programs should be of concern to patients, health care professionals, administrators, and others who work in managed care pharmacy since these programs are widely used. Little has changed since 1993, when Kotzan, McMillan, Jankel, and Foster lamented: "The long-term impact of PA programs has not been documented. If the drug programs are devised solely on the basis of economic consideration without regard for medical consequences, then it is likely that more expensive services will replace those expensive drugs removed from the formulary." 16 Why is there a lack of rigorous evaluations of PA programs? Ray has reflected on the general problem of inadequate health policy evaluations and concluded that a primary barrier is politics; conducting a randomized, controlled trial is an admission of uncertainty. 21 The persons or organizations involved in PA programs may have a vested interest in the success of their programs. Moreover, expensive randomized controlled trials may not be practical for many organizations, although repeated time-series analyses, such as the one conducted by Smalley and colleagues, may be possible.
One can understand the reluctance to measure humanistic outcomes of PA programs, such as satisfaction, given that PA is an administrative policy. Still, measuring what happens to patients who are denied a PA request would be valuable. Fortunately, some MCOs are now trying to improve physician and patient satisfaction with PA programs, some by automating the PA process to eliminate paperwork or pharmacist intervention. 22, 23 Finally, another barrier to quality evaluations is that some organizations may have difficulty in separating the outcomes of a PA program from those of the total formularymanagement system.
Why is there a need for more PA program evaluations that measure all three types of health-related outcomes? The principal reason is to determine how PA programs affect clinical and humanistic outcomes. Proof that PA programs improve patient outcomes would more strongly support their use. If they affect patient outcomes negatively, all stakeholders should reassess their use. Failure to measure the clinical outcomes of PA programs is of special concern: Our literature search found no published studies, and just one presentation abstract, that measured clinical outcomes outside the hospital. 24 Secondly, evaluation of programs and policies is a key part of a continuous quality improvement (CQI) philosophy, where benchmarks are determined and an attempt made to improve performance to exceed those benchmarks.
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As Phillips and Larson acknowledge, currently there are not even PA program benchmarks for such basic outcomes as processing times, approval rates, and administrative costs. 5 Standard principles for PA programs could be helpful, perhaps like those recently developed for drug-formulary systems by AMCP and other organizations. 28 Setting, and reporting on, standards should lead to increased accountability and transparency for PA programs. The accountability that must clearly become a priority for each stakeholder involved in putting such programs in place should include continual monitoring to determine if the program's mandate is being achieved.
The burden of proof whether PA programs improve patient outcomes should be on those who have programs in place, even if this is a difficult process. As Hepler says, "It may be painful to be objective about our own sacred cows." 29 Program evaluation is especially urgent given that many policies that regulate access to and utilization of pharmaceuticals can have unintended neg-Prior Authorization Programs: A Critical Review of the Literature ative outcomes. 12 PA programs that direct prescribers to follow evidence-based clinical practice should, in theory, lead to positive clinical and HRQoL outcomes. Yet, as at least two of the studies we reviewed acknowledged, because these outcomes were not measured, we cannot be certain whether PA programs have a positive or a negative effect on these outcomes. 5, 18 Given these important but still unanswered questions, now would appear to be an opportune time for evaluation of all policies that restrict prescribing, including PA.
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imitations In any analysis of critical literature, some may differ with the inclusion/exclusion criteria or identify studies that have been omitted. We tried to minimize these problems by making our initial search as broad as possible through the use of multiple literature-retrieval methods and by making our criteria fairly conservative. As with any literature review, we are limited by inherent publication biases to publish only statistically significant results. Finally, we did intend to conduct a meta-analysis, but this proved impossible given the inconsistency in the description of the study samples and outcomes.¨C onclusion From a critical review of the literature, PA programs appear to reduce drug-related costs. There is some evidence that they may also reduce non-drug-related costs, but little evidence that they improve clinical or humanistic outcomes. Most existing studies have severe methodological limitations. There has been not one randomized controlled study to better establish the relationship of PA programs to these health-related outcomes. Resources for thorough program evaluations may be scarce, but an uninformed acceptance of PA programs without consideration of their effects on health outcomes may be suboptimal at best, and dangerous at worst.
